In an attempt to address the issue of the protective status of the host, we chose to screen sera from patients recovering from either Type A or B tularemia. Since the incidence of re-infection is extremely low, these individuals may be assumed to be protected against re-infection. With this assumption, antigens common to patient and vaccinee sera are more likely to serve as potential correlates of protection.